Y-Biologics Inc.

As of June 30, 2026, Y-Biologics Inc. carries a market capitalization of 182.14B, placing it among publicly traded companies globally. Its enterprise value stands at 160.08B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Y-Biologics Inc. has 15.18M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 57.41, and the price-to-book ratio stands at 10.59.

These figures are as of June 30, 2026. The EV/Sales ratio of 50.49 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 160.08B versus a market cap of 182.14B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Y-Biologics Inc. maintains a current ratio of 23.81, meaning it holds 23.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 95.54, indicating elevated leverage, while an interest coverage ratio of -6.47 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Y-Biologics Inc. posted a negative return on equity (ROE) of -297.87, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -145.01, reflecting losses generated across the asset base. The company generates approximately 56.11M in revenue per employee across its workforce of 56.50, a quick read on workforce productivity versus industry peers.

As of the close on October 23, 2026, Y-Biologics Inc.'s stock has declined approximately 45.82% over the past 52 weeks. The 50-day moving average sits at 8,710.00, while the 200-day moving average is 17,630.45.

Over the twelve months ended June 30, 2026, Y-Biologics Inc. generated 3.17B in revenue and converted that into -49.95B in net income, yielding earnings per share of -3,293.43. EBITDA reached -11.26B, while operating income came in at -13.18B.

As of June 30, 2026, Y-Biologics Inc. holds 38.49B in cash and equivalents against 16.43B in total debt, resulting in a net debt position of 13.59B. Total book value stands at 17.20B, with working capital of 38.03B providing operational flexibility.

Y-Biologics Inc. produced -9.06B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.97B in capital expenditures, free cash flow totaled -11.02B - equivalent to -726.76 per share.

Over the twelve months ended June 30, 2026, Y-Biologics Inc. posted a gross margin of 83.87, reflecting its pricing power and cost economics. The operating margin of -415.87 and net profit margin of -1,575.63 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -6.06: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -22.12, meaning Y-Biologics Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Y-Biologics Inc. has an Altman Z-Score of -1.50, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.